GLP1R and diabetes mellitus: In the European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) and in the ESC/European Association of Preventive Cardiology (EAPC) guidelines, GLP-1 RA and SGLT2i are included in pharmacological management algorithms as first-line treatment for patients with high or very high CV risk [26, 27].